Drugmaker Teva hires Lundbeck CEO Schultz to restore its health

By Steven Scheer and Stine JacobsenJERUSALEM/COPENHAGEN (Reuters) - Teva poached Lundbeck's Kare Schultz as its new chief executive on Monday, handing the drugs industry veteran the urgent task of convincing investors of the struggling Israeli firm's future.A costly acquisition spree in recent years has saddled Teva with huge debts and eroded shareholder confidence in the generic drugs maker, whose stock has dropped by 50 percent since early August when it cut both its forecasts and its dividend